Aldeyra Therapeutics, Inc. (ALDX:NASDAQ) closed at $0.900 on October 13, 2026, down 0.66% on the day. The stock trades 84.8% below its 52-week high of $5.93 and 4.4% above its 52-week low of $0.862. Over the past year, it lost 83.1%. Aldeyra Therapeutics, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -1.77% | -38.37% | -47.69% | -50.01% | -83.15% |
In 252 trading sessions since October 13, 2025, ALDX closed higher on 106 days (42%). Its best day was December 16, 2025 (+33.08%) and its worst was March 17, 2026 (-70.69%). The stock moved 10% or more in a single session 19 times.
Aldeyra Therapeutics, Inc., a biotechnology company, focuses on the development of products for diseases caused by inflammation and inborn errors of metabolism in the United States and internationally. It is developing NS2, a small molecule designed to trap and allow for the degradation of aldehydes. Its product is used for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, sjogren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was founded in 2004 and is based in Lexington, Massachusetts.
Find more stocks like ALDX with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.